Onyx: Deal Or No Deal, Time For A Payoff Seeking Alpha The study included patients who were eligible for a stem cell transplant. It was interesting to learn that these patients were able to remain on the Carflizomib combination and achieve responses similar to, or better even than those observed after stem ... |
